Pfizer paid $650M up front in late 2020 deal to share rights to therapy, also approved for uterine fibroids indication

ICER says report highlights ‘bad apples.’ Industry says it is misleading

Pfizer’s partnership with Myovant sends another signal that plenty of opportunity still exists in women’s health, despite recent pharma exits. In teaming up with Pfizer Inc. (NYSE:PFE)

Gilead takes stake in Tango, expands 2018 dealGilead Sciences Inc. (NASDAQ:GILD) million has expanded its 2018 deal with Tango Therapeutics Inc. to cover worldwide options over seven years from

The targets and indications CAR T developers are exploring to get to efficacy in solid tumors